Press release
Androgenic Alopecia Therapeutics - Pipeline Analysis GSK, Almirall, Allergan, RepliCel Life Sciences Inc.
Download free report sample at: https://www.psmarketresearch.com/market-analysis/androgenic-alopecia-therapeutics-pipeline-analysis/report-sample
Androgenic alopecia is a genetic disorder that affects both men and women and is characterized by hair loss in both the sexes. Androgenic alopecia is also known as male-pattern baldness in men and female-pattern baldness in women. The predisposing factors for androgenic alopecia include allergies, burns, irritants, injuries, infections, and toxins.
*Various Collaborations for Androgenic Alopecia Therapeutics Drug Development
In August 2017, Aclaris Therapeutics, Inc. acquired Confluence Life Sciences, Inc., a privately held biotechnology company for a consideration of $10 million in cash and issued approximately 350,000 shares of its common stock, with a value of approximately $10 million on the closing date to expand the dermatological pipeline of Aclaris Therapeutics, Inc.
Browse report at: https://www.psmarketresearch.com/market-analysis/androgenic-alopecia-therapeutics-pipeline-analysis
Some of the key players developing drugs for the treatment of androgenic alopecia therapeutics include GlaxoSmithKline plc, Almirall S.A., Allergan plc, RepliCel Life Sciences Inc. and others.
*Positive Clinical Results of Androgenic Alopecia Therapeutics Candidates
The positive clinical results of androgenic alopecia drug candidates have been driving the pipeline growth. Many drug candidates have shown positive clinical results and are proceeding further towards development. In February 2016, Cassiopea S.p.A. reported the top-line results from the proof of concept, Phase II clinical trial of Breezula (CB-03-01), in androgenic alopecia and it was found that Breezula, met both its two pre-defined co-primary efficacy endpoints, increase in total area hair count within 1 cm2 (TAHC) and subject hair growth assessment (HGA) at six months. Breezula also demonstrated favorable safety profile.
Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=androgenic-alopecia-therapeutics-pipeline-analysis
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Androgenic Alopecia Therapeutics - Pipeline Analysis GSK, Almirall, Allergan, RepliCel Life Sciences Inc. here
News-ID: 1414153 • Views: …
More Releases from P&S Intelligence
Modular Automation Market Poised for Robust Growth Amid Industry 4.0 Transformat …
According to the latest market research study published by P&S Intelligence, the global modular automation market is on an impressive growth trajectory, expected to generate USD 6.3 billion in 2024 and expand at a CAGR of 8.7% to reach USD 12.1 billion by 2032. This surge is driven by rising demand for flexible, cost-efficient manufacturing solutions and the accelerating integration of Industry 4.0 technologies.
As manufacturing landscapes evolve with rapid changes…
U.S. ESG Investments Market Set to Skyrocket: $16 Trillion by 2032
According to the latest market research study published by P&S Intelligence, the U.S. Environmental, Social, and Governance (ESG) investments market is experiencing a significant surge, with projections indicating an increase from $6.5 trillion in 2024 to an estimated $16.0 trillion by 2032. This represents a robust compound annual growth rate (CAGR) of 12.1% over the forecast period.
According to a comprehensive analysis by P&S Intelligence, the market's expansion is driven…
Facility Management in the U.K. Booms with 14.1% CAGR as Demand Soars Across Sec …
According to the latest market research study published by P&S Intelligence, the U.K. facility management market is poised for significant growth, with projected revenues reaching USD 2,743.3 million in 2024 and expected to soar to USD 6,038.4 million by 2030, reflecting a robust CAGR of 14.1% during the forecast period.
This expansion is fueled by a surge in demand across both public and private sectors. According to the RICS U.K.…
Point-of-Sale Software Market in the U.S. Set to Grow by 9.7% CAGR, Boosted by O …
According to the latest market research study published by P&S Intelligence, the U.S. point-of-sale (POS) software market, valued at USD 4.7 billion in 2024, is poised for significant growth over the coming years, with projections estimating it will reach USD 9.8 billion by 2032, expanding at a compound annual growth rate (CAGR) of 9.7%. This growth is attributed to rapid technological advancements, a surge in mobile and cloud-based POS systems,…
More Releases for Androgenic
Androgenic Alopecia Drug Market Rising Demand and Growth Forecast Through 2033
The Androgenic Alopecia Drug market was valued at USD 2.27 billion in 2023 and is projected to reach approximately USD 3.69 billion by 2033, growing at an estimated CAGR of about 5.0% from 2024 to 2033.
Androgenic Alopecia Drug Market Overview
The Androgenic Alopecia Drug market is expanding steadily due to the increasing prevalence of pattern hair loss and rising interest in aesthetic treatments. Common therapies such as minoxidil and finasteride remain…
Androgenic Alopecia Therapeutics Market Analysis and Future Prospects for 2030
The world of the androgenic alopecia therapeutics market is a complex and ever-evolving landscape, shaped by consumer demands and technological advancements. In this report, we delve into the depths of this market to provide a profound and comprehensive analysis, catering to a diverse audience that includes manufacturers, suppliers, distributors, and investors. Our primary goal is to empower industry stakeholders with invaluable insights to make informed decisions in a rapidly changing…
Androgenic Alopecia Therapeutics Market Trends, Size, Massive Growth Opportuniti …
Market Intelligence Data worked with the exploring on global Androgenic Alopecia Therapeutics Market considering an unexpectedly long time from 2022-2028. The evaluation approaches followed are made and plan to give a more essential picture of the diligent moreover as advancing toward changes that the Androgenic Alopecia Therapeutics market is and will be familiar with in the really insinuated figure stretch of time.
The report sets sure to consider its clients &…
Insights on the Androgenic Alopecia Drug Market to 2027 | Industry Statistics, E …
The global androgenic alopecia drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The growing prevalence of hair loss, technological advancements in alopecia treatment, and the rise in prevalence of chronic diseases that are associated with hair loss are some of the major factors driving the market. According to data published by the American Hair Loss Association, it was stated that over 95.0% of…
Androgenic Alopecia Therapeutics Pipeline Analysis Report -Clinical Trials & Res …
The study analyzed that the androgenic alopecia therapeutics pipeline comprises approximately 24 active drug candidates in different stages of development. Androgenic alopecia is a genetic disorder that affects both men and women and is characterized by hair loss in both the sexes. Androgenic alopecia is also known as male-pattern baldness in men and female-pattern baldness in women. The predisposing factors for androgenic alopecia include allergies, burns, irritants, injuries, infections, and…
Global Androgenic Alopecia Clinical Trials Industry Review :H1-2017 | Diseases M …
Market Research Hub's clinical trial report, Global Androgenic Alopecia Clinical Trials Review, H1, 2017, provides an overview of Androgenic Alopecia clinical trials scenario. This report provides top line data relating to the clinical trials on Androgenic Alopecia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.
Request Free Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068385
The report offers coverage of disease clinical trials by region, country (G7…
